Anti-bladder cancer and COVID-19 potentials of pachymic acid: clinical features and therapeutic targets

Abstract

ABSTRACT Pachymic acid, as one of bioactive ingredients in Poria Cocos, has been evidenced preclinically with pharmacological benefits including anti-bladder cancer action. Additionally, pachymic acid has been initiatorily identified in Chinese prescriptions applied for coronavirus disease 2019 (COVID-19) treatment. However, the molecular mechanisms and pharmacological targets associated with mitochondrial functions in pachymic acid against bladder cancer and COVID-19 have not been explored. In this study, network pharmacology and molecular docking detections were employed to identify common, candidate, and core targets that were related to pachymic acid treating bladder cancer COVID-19. Enrichment determinations using core target genes were used to reveal the anti-bladder cancer and COVID-19 molecular mechanisms exerted by pachymic acid. Firstly, all 1150 differentially expressed genes among bladder cancer and COVID-19 were ascertained and a risk score with key genes characterized by different risk groups was established. Furthermore, current study highlighted pachymic acid as a potential compound for anti-bladder cancer and COVID-19. Network pharmacology approaches ascertained ten key targets for pachymic acid against bladder cancer and COVID-19. Molecular docking findings showed that pachymic acid presented effectively binding abilities to key target proteins of chemokine (CC-motif) ligand 2 (CCL2), thrombospondin-1 (THBS1), matrix metallopeptidase 1 (MMP1) in severe acute respiratory syndrome coronavirus 2 ;(SARS-CoV-2). Our study indicates that pachymic acid may be used for treatment of bladder cancer and COVID-19 through increasing tumor immunity and inhibiting SARS-CoV-2 replication based on present bioinformatics findings.